No. The shockwaves target the kidneys externally. The procedure is safe, painless, non-invasive, requires no anesthesia, no medication, no surgery, no recovery period—and no dialysis. Each session takes under an hour.

Not recommended. This therapy focuses on preserving kidney function before dialysis becomes necessary.

Shockwave therapy is not recommended for individuals with transplanted kidneys.

If the patient is in Stage 5 but has not yet started dialysis, they may consider Omnispec Model Vascuspec Type Nephrospec treatment. While Stage 5 kidneys can no longer effectively filter waste, stimulating microvascular growth may delay the need for dialysis.

However, results vary per individual and shockwave therapy cannot replace dialysis. Research is still lacking on Stage 5-specific outcomes.

International studies show promising results. Upon completing the recommended program :
- Average reduction in blood pressure: 10–16 mmHg.
- Patients in stages 3–4 often maintain stable eGFR levels.
- Capillary growth improvement depends on individual response but trends positively.

Research suggests that six sessions over three weeks (one full course) can :
- Reduce both systolic and diastolic blood pressure in hypertensive kidney patients
- Stabilize kidney function as indicated by eGFR, sustained up to 12 months post-treatment
Yearly treatment is advised to prolong kidney function and postpone dialysis initiation.

Omnispec Model Vascuspec Type Nephrospec uses Electro-Hydraulic Acoustic Therapy (eHAT) with ultrasound guidance, targeting 8 specific areas of both kidneys. It focuses directly on the kidneys. The clinic only provides information on Omnispec Model Vascuspec Type Nephrospec technology and not other alternatives.

They both use shockwaves, but Nephrospec emits low-intensity waves tailored for kidney application, reaching deep renal tissue.

*Certified under CE standards (Europe), authorized for use across European countries.

One course consists of 6 sessions over 3 weeks. This may help stabilize kidney decline for up to one year.

Annual courses are recommended to maximize delay in kidney deterioration. Results vary per patient’s condition.

It’s the world’s first shockwave device developed specifically for kidney stimulation—a cutting-edge innovation. Research shows its potential in helping stage 3–4 kidney disease patients stabilize eGFR and reduce blood pressure.

The device is costly, and skilled operators—currently limited in Thailand—are required. That said, the price may decrease over time as demand rises.